![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/20/2884798/0/en/PolarityTE-Secures-22-5-Million-Financing-to-Advance-SkinTE-Phase-III-Pivotal-Study-in-Diabetic-Foot-Ulcers.html
https://www.globenewswire.com//news-release/2024/02/26/2835136/0/en/PolarityTE-Announces-First-Subject-Screened-in-Phase-III-Pivotal-Study-Evaluating-Investigational-New-Drug-SkinTE-in-Diabetic-Foot-Ulcers.html
https://www.biospace.com/article/releases/polarityte-confirms-receipt-of-unsolicited-non-binding-offer-to-acquire-the-company/?s=79
https://www.prnewswire.com/news-releases/polarityte-reports-second-quarter-2022-financial-results-and-provides-business-update-301604447.html
https://www.prnewswire.com/news-releases/polarityte-reports-first-quarter-2022-financial-results-and-provides-business-update-301547407.html
https://www.prnewswire.com/news-releases/polarityte-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-skinte-301546677.html
https://www.prnewswire.com/news-releases/polarityte-announces-submission-of-complete-response-to-fdas-clinical-hold-correspondence-for-skinte-investigational-new-drug-application-301447890.html
https://www.prnewswire.com/news-releases/polarityte-provides-update-on-investigational-new-drug-application-301394760.html
https://seekingalpha.com/news/3736627-polarityte-makes-ceo-and-cmo-appointments
https://www.businesswire.com/news/home/20210824005288/en/PolarityTE-Provides-Update-on-U.S.-FDA-Investigational-New-Drug-Application-for-SkinTE%C2%AE